skip to the main content
Contact Us
Go Search
Go Search Menu

Prostate Specific Antigen (PSA)

Screening for the prostate cancer & monitoring the effects of the treatment

This test helps in the early detection of prostate diseases such as enlarged prostate and prostatitis and prostate cancer by quantifying PSA in male blood, as well as observation of treatment effects and monitoring of recurrence.

Diagnosis diseases
Prostate Cancer, Prostatitis, benign prostatic hyperplasia (BPH)
  • CE 0123 (Self-testing)
  • ANVISA ichroma™

Available Instruments

AFIAS-1 AFIAS-6 ichroma™ II ichroma™ III

About Using Reagent

  • Sample Types

    whole blood, plasma, serum

  • Reaction Time

    15 mins

  • Detection Range

    AFIAS (0.5 – 100 ng/ml)
    ichroma™ ( S/P : 0.1 – 100 ng/ml) ( WB : 0.5 – 100 ng/ml)

  • Indication

    Prostatitis, benign prostatic hyperplasia (BPH), Prostate Cancer

In Your Medical Field

The PSA test is only one test for screening for signs of prostate cancer. It is much less invasive than the digital rectal exam that may ensue depending on the result of the PSA test. Though not specific to prostate cancer, the PSA test can provide vital primary information about prostate cancer in just 15 minutes in a POC settings.

Related Reference

The Performance of the POCT I-CHROMA™ PSA Method Using Internal and External Quality Assessment Schemes_UKNEQAS And RIQAS
Performance of the point of care test (POCT) i-CHROMA PSA method using internal and external quality assessment schemes_(UKNEQAS) and (RIQAS)
An Evaluation of the Point-of-Care Test i-CHROMA Prostate-Specific Antigen Method for Screening in the Community

Our Efforts to be with you